• PMH24 HEALTH CARE UTILIZATION OF MAJOR DEPRESSIVE DISORDER PATIENTS

    Nov 1, 2010, 00:00

  • PSS10 HEALTH-STATE UTILITIES AND WILLINGNESS TO PAY AND THEIR ASSOCIATION WITH HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH PSORIASIS IN TAIWAN

    Nov 1, 2010, 00:00

  • PHP15 RISK-SHARING SCHEMES WORLDWIDE- A LANDSCAPE ANALYSIS OF HEALTH OUTCOMES-BASED REIMBURSEMENT AGREEMENTS

    Nov 1, 2010, 00:00

  • PIH27 ADHERENCE TO PRESCRIPTION MEDICATIONS IS HIGHER WITH USE OF A GENERAL PRACTITIONER

    Nov 1, 2010, 00:00

  • PCN25 DID THE UPTAKE OF NEW TREATMENT OPTIONS CHANGE THE TREATMENT STRATEGY IN PATIENTS WITH COLORECTAL CANCER AND PRIMARY NONRESECTABLE METASTASES? THE RESULTS OF LARGE POPULATION-BASED SURVEY IN GERMANY 2006-2007

    Nov 1, 2010, 00:00

  • PDB76 HEALTH RELATED QUALITY OF LIFE OF TYPE 2 DIABETES MELLITUS PATIENTS IN THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM- FIRST RESULTS OF DIAPS79 STUDY

    Nov 1, 2010, 00:00

  • PSY14 REAL-WORLD USE OF DULOXETINE FOR CHRONIC LOW BACK PAIN- TREATMENT PATTERN AND COSTS

    Nov 1, 2010, 00:00

  • PDB18 EVALUATION OF CLINICAL INERTIA IN DIABETES CARE OF NON-INSULIN-DEPENDENT TYPE 2 DIABETIC PATIENTS

    Nov 1, 2010, 00:00

  • PCN131 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN CERVICAL CANCER- CLINICAL SIGNIFICANCE AND METHODOLOGICAL ISSUES

    Nov 1, 2010, 00:00

  • PIH38 STUDY OF THE DEGREE OF SATISFACTION OF PATIENTS WITH URINARY DISORDERS, EVOCATIVE OF BPH

    Nov 1, 2010, 00:00

  • PCN29 EPIDEMIOLOGY AND HEALTH-CARE UTILIZATION FOR RESECTED SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (SCCHN) IN SOUTH KOREA

    Nov 1, 2010, 00:00

  • PHP42 CURRENT AND FUTURE USE OF PHARMACOECONOMIC AND OUTCOMES RESEARCH DATA IN DECISION-MAKING IN THE USA

    Nov 1, 2010, 00:00

  • PMS58 CLINICAL OUTCOMES AND CHANGES IN QUALITY OF LIFE IN WOMEN WITH OSTEOPOROSIS TREATED WITH TERIPARATIDE- 36 MONTH RESULTS OF THE FRENCH PATIENTS PARTICIPATING IN THE EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS)

    Nov 1, 2010, 00:00

  • PMH68 TREATMENT DISCONTINUATION IN A LOCAL MENTAL HEALTH CARE SYSTEM IN GERMANY FROM THE PATIENTS PERSPECTIVE

    Nov 1, 2010, 00:00

  • PSS7 ECONOMIC EVALUATION ON VISION SCREENING FOR PRESCHOOL CHILDREN

    Nov 1, 2010, 00:00

  • PCN31 THE PREDICTIVE AND PROGNOSTIC ROLE OF ERCC1 IN ADVANCED NON-SMALL CELL LUNG CANCER- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2010, 00:00

  • PHP69 MOBILE MEDICAL RECORD-A LIFE SAVING TOOL

    Nov 1, 2010, 00:00

  • PHP71 PREDICTING OUTCOMES AMONG PATIENTS WITH PROLONGED MECHANIC VENTILATION- A DISCRIMINATION MODEL BASED ON LONGITUDINAL HEALTH INSURANCE REGISTRATION AND CLAIMS DATA

    Nov 1, 2010, 00:00

  • PSY1 DEVELOPMENT OF A CO-MORBIDITY SCALE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

    Nov 1, 2010, 00:00

  • PIN23 DIFFERENTIAL PRICING POLICY AND ITS IMPACT ON TREAMENT COSTS OF VISCERAL LEISHMANIASIS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM

    Nov 1, 2010, 00:00

  • PUK35 PATIENTS WITH BPH- RESULTS AT 6 MONTHS FOLLOWING TREATMENT WITH PHYTOTHERAPY VERSUS OTHER TREATMENTS

    Nov 1, 2010, 00:00

  • PMH19 BURDEN OF ILLNESS OF TREATMENT RESISTANT DEPRESSION

    Nov 1, 2010, 00:00

  • PGI22 MAPPING PAC-QOL SCORES ONTO THE EQ-5D

    Nov 1, 2010, 00:00

  • PCN73 COST-EFFECTIVENESS ANALYSIS OF SUPERIOR HYPOGASTRIC PLEXUS INHIBITION IN CANCER PATIENTS WITH VISCERAL PAIN IN LOWER ABDOMEN

    Nov 1, 2010, 00:00

  • PMC45 GLOBAL INDUSTRY USE OF ELECTRONIC PATIENT-REPORTED OUTCOME INSTRUMENTS- PRELIMINARY RESULTS FROM A 2010 EPRO SURVEY

    Nov 1, 2010, 00:00

  • PMS77 THE DETERMINANTS OF SOCIAL ROLES AMONG RHEUMATOID ARTHRITIS PATIENTS-DATA FROM THE NDB PORTUGAL COHORT

    Nov 1, 2010, 00:00

  • PSY6 THE ICATIBANT OUTCOME SURVEY-A PROSPECTIVE STUDY OF SAFETY AND EFFECTIVENESS OF ICATIBANT IN A SETTING IN PATIENTS WITH HEREDITARY ANGIOEDEMA

    Nov 1, 2010, 00:00

  • PND33 REFILL-ADHERENCE RATES OF ANTIPARKINSON MEDICATION IN THE PRIVATE HEALTH CARE SECTOR OF SOUTH AFRICA

    Nov 1, 2010, 00:00

  • CN4 HPV-BASED PRIMARY CERVICAL CANCER SCREENING IN GERMANY. COST-EFFECTIVENESS RESULTS FROM A DECISION-ANALYTIC MODELING STUDY

    Nov 1, 2010, 00:00

  • PIH24 INDIRECT COSTS OF PREGNANCY, PARTURITION AND PUERPERIUM IN POLAND

    Nov 1, 2010, 00:00

  • PHP32 PROBABILISTIC SENSITIVITY ANALYSIS-A NECESSARY EXTRA?

    Nov 1, 2010, 00:00

  • PCV141 A NOVEL METHOD FOR ESTIMATING THE EFFECTS OF ADHERENCE TO ANTIHYPERTENSIVES AND DURATION OF DRUG ACTION ON CARDIOVASCULAR RISK

    Nov 1, 2010, 00:00

  • DB4 ECONOMIC EVALUATION OF THIAZOLIDINEDIONES AS ADD-ON THERAPY FOR TREATMENT OF TYPE 2 DIABETIC PATIENTS IN THE TAIWANESE NATIONAL HEALTH INSURANCE SYSTEM

    Nov 1, 2010, 00:00

  • CN2 REAL-WORLD COST-EFFECTIVENESS OF OXALIPLATIN IN STAGE III COLON CANCER- A SYNTHESIS OF TRIAL DATA WITH DATA FROM DAILY CLINICAL PRACTICE

    Nov 1, 2010, 00:00

  • PDB28 HEALTH INSURANCE COST OF DIABETES MELLITUS IN HUNGARY- A COST OF ILLNESS STUDY

    Nov 1, 2010, 00:00

  • PIH19 TRENDS IN COST-EFFECTIVENESS STUDIES OF HIGH BUDGET IMPACT DRUGS

    Nov 1, 2010, 00:00

  • PND42 THE RELATIONSHIP BETWEEN SOME INDICATORS INFLUENCING THE QUALITY OF LIFE OF PEOPLE WITH DOWNS SYNDROME LOOKED AFTER IN THE FAMILY AND PARENTAL QUALIFICATION IN CONNECTION WITH A STUDY CARRIED OUT IN HUNGARY

    Nov 1, 2010, 00:00

  • PUK17 PATIENT CO-MORBIDITIES AFFECT THE COST OF DIALYSIS PATIENTS IN BELGIUM

    Nov 1, 2010, 00:00

  • PSS20 COST-UTILITY ANALYSIS OF A PRN (AS NEEDED) TREATMENT SCHEDULE WITH RANIBIZUMAB (LUCENTIS) IN WET AMD BASED ON CLINICAL EVIDENCE

    Nov 1, 2010, 00:00

  • PCN118 UTILITY VALUES FOR CHRONIC MYELOID LEUKAEMIA-CHRONIC PHASE (CML-CP) HEALTH STATES FROM THE GENERAL PUBLIC IN THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PCN57 EXAMINING PATIENT-BASED COSTS FOR IRINOTECAN CHEMOTHERAPY- UK PRACTICE-BASED MICROCOSTING STUDY

    Nov 1, 2010, 00:00

  • PMC15 A NOVEL METHOD FOR COMBINING THREE CURRENT ESTIMATION APPROACHES TO PHARMACEUTICAL PRICING

    Nov 1, 2010, 00:00

  • PMS10 PREVALENCE OF GOUT IN THE US GENERAL POPULATION-THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES) 2007-2008

    Nov 1, 2010, 00:00

  • PND1 INDIRECT COMPARISON OF ADVERSE EVENTS AND DROPOUT RATES FOR EARLY PARKINSONS DISEASE (PD) MONOTHERAPY TRIALS- PRAMIPEXOLE, ROPINIROLE AND RASAGILINE

    Nov 1, 2010, 00:00

  • PDB7 ESTIMATED COSTS OF INCLUDING GROWTH HORMONE REPLACEMENT THERAPY INTO THE UNIVERSAL COVERAGE BENEFIT PACKAGE IN THAILAND

    Nov 1, 2010, 00:00

  • PHP120 DESCRIPTION AND EVALUATION OF THE KNOWLEDGE OF THE BRASILIA POPULATION FOR THE POLITICS OF ECONOMIC MEDICINE REGULATION IN BRAZIL

    Nov 1, 2010, 00:00

  • PDB60 HEALTH ECONOMIC EVALUATIONS COMPARING THE BASAL INSULIN ANALOGUES INSULIN GLARGINE (GLA) AND INSULIN DETEMIR (DET) IN INTENSIFIED INSULIN THERAPY (ICT) IN PATIENTS WITH TYPE 1 DIABETES- A SYSTEMATIC REVIEW

    Nov 1, 2010, 00:00

  • PCV72 COST-EFFECTIVENESS OF EXTENDED-RELEASE NICOTINIC ACID/ LAROPIPRANT AS MONOTHERAPY VERSUS EZETIMIBE MONOTHERAPY IN PATIENTS WITH MIXED DYSLIPIDAEMIA IN SCOTLAND

    Nov 1, 2010, 00:00

  • PDB49 PHARMACOECONOMICS MODELING OF LONG TERM RESULTS OF TYPE 2 DIABETES MELLITUS TREATMENT IN PATIENTS USING MODERN INSULIN ANALOGUES IN CONTRAST TO ORAL ANTIDIABETIC DRUGS OR DIET

    Nov 1, 2010, 00:00

  • PCN9 OBSERVATIONAL STUDY OF PATIENTS WITH NON SMALL CELL LUNG CANCER (NSCLC) TREATED BY ERLOTINIB- CLINICAL PRACTICES AND MAIN OUTCOMES IN FRANCE

    Nov 1, 2010, 00:00

  • PMH9 BUDGET IMPACT ANALYSIS OF SERTINDOLE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND

    Nov 1, 2010, 00:00

  • PDB41 COST-EFFECTIVENESS OF LIRAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES IN THE SLOVAK REPUBLIC

    Nov 1, 2010, 00:00

  • PHP36 ANALYSIS OF THE TECHNICAL EFFICIENCY IN THREE TEACHING HOSPITALS IN MALAYSIA

    Nov 1, 2010, 00:00

  • PDB9 COST-EFFECTIVENESS OF CSII IN CHINA

    Nov 1, 2010, 00:00

  • PMH12 COST IMPACT OF INITIATING PREGABALIN TREATMENT IN SWEDISH PATIENTS WITH GENERALIZED ANXIETY DISORDER

    Nov 1, 2010, 00:00

  • PMS13 RECENT TRENDS IN NUMBERS OF PRIMARY HIP/KNEE ARTHROPLASTIES PERFORMED IN GERMANY AND THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PDB65 THE METHODOLOGICAL QUALITY AND EFFECTIVENESS OF ADHERENCE INTERVENTIONS- A REVIEW OF DIABETES TYPE II INTERVENTIONS

    Nov 1, 2010, 00:00

  • PHP29 ASSESSMENT OF THE ORPHAN DRUG PRICING AND REIMBURSEMENT LANDSCAPE IN THE ASIA PACIFIC REGION

    Nov 1, 2010, 00:00

  • PUK11 A COST EVALUATION OF PERITONEAL DIALYSIS AND HEMODIALYSIS IN THE TREATMENT OF ESRD IN SO PAULO, BRAZIL

    Nov 1, 2010, 00:00

  • PMH10 COST-EFFECTIVENESS OF SERTINDOLE AMONG ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA IN SOUTH KOREA

    Nov 1, 2010, 00:00

  • PDB87 STANDARDS FOR THE ASSESSMENT OF ANTIDIABETIC DRUGS-THE IQWIG PERSPECTIVE

    Nov 1, 2010, 00:00

  • IN2 COST-EFFECTIVENESS OF DIFFERENT STRATEGIES FOR TUBERCULOSIS CONTROL PROGRAMS IN THAILAND

    Nov 1, 2010, 00:00

  • PDB54 COMPARISON OF TREATMENT COSTS BETWEEN BASAL-SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE (GLA) AND BOT WITH INSULIN DETEMIR (DET) IN PATIENTS WITH TYPE 2 DIABETES (T2D)- ECONOMIC EVALUATION BASED ON THE RESULTS OF THE INSULIN GL ...

    Nov 1, 2010, 00:00

  • PUK16 COST OF ILLNESS ASSOCIATED WITH RENAL TRANSPLANTATION AND DIALYSIS IN END STAGE RENAL DISEASE IN THE UNITED STATES

    Nov 1, 2010, 00:00

  • PDB57 LOWER TREATMENT COSTS WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN TYPE 1 DIABETES PATIENTS TREATED WITH A BASAL-BOLUS REGIMEN IN GERMANY

    Nov 1, 2010, 00:00

  • PHP43 ASSESSING THE ADDED VALUE OF NEW DRUGS- A MULTIDIMENSIONAL APPROACH

    Nov 1, 2010, 00:00

  • PIN13 LONG-TERM ECONOMIC AND CLINICAL BURDEN OF COMPLICATED INVASIVE MENINGOCOCCAL DISEASE- EVIDENCE FROM A UNITED STATES MANAGED CARE POPULATION

    Nov 1, 2010, 00:00

  • PMS7 DETERMINANTS OF TNF INHIBITOR DOSE ESCALATION IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2010, 00:00

  • PMH45 DISCONTINUATION OF DIFFERENT ANTIPSYCHOTIC MEDICATIONS AFTER DISCHARGE FROM ACUTE CARE FOR PERSONS WITH SCHIZOPHRENIA

    Nov 1, 2010, 00:00

  • PMH17 COMPARISON OF HRQOL BETWEEN PATIENT RECEIVING METHADONE MAINTENANCE THERAPY (MMT) AND REHABILITATION PROGRAM

    Nov 1, 2010, 00:00

  • PMC56 IMPROVED SURVIVAL CURVE FITS TO SUMMARY DATA FOR ECONOMIC EVALUATIONS

    Nov 1, 2010, 00:00

  • ME2 VALIDATING THE ACCURACY OF A NOVEL METHOD FOR IDENTIFYING HEALTH CARE-ASSOCIATED INFECTIONS

    Nov 1, 2010, 00:00

  • PCV136 ATRIAL FIBRILLATION MANAGEMENT PATTERNS IN GREECE

    Nov 1, 2010, 00:00

  • PMH35 COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATE AND SEVERE ALZHEIMERS DISEASE PATIENTS WITH AGITATION, AGGRESSION AND PSYCHOSIS-THE UK EXAMPLE

    Nov 1, 2010, 00:00

  • PDB31 THE IMPACT OF NEUROMONITORING ON THYROID SURGERY COSTS

    Nov 1, 2010, 00:00

  • PGI8 ANTIBIOTIC PRESCRIBING PRACTICES OF PRIMARY CARE PRESCRIBERS FOR DIARRHEA NI NEW DELHI, INDIA

    Nov 1, 2010, 00:00

  • PSY50 HEALTH-RELATED QUALITY OF LIFE, HEALTH UTILITIES, AND WORK PRODUCTIVITY ASSOCIATED WITH SPECIFIC OBESITY-RELATED COMORBIDITIES

    Nov 1, 2010, 00:00

  • PCN23 ECONOMIC EVALUATION ON LIQUID-BASED CYTOLOGY IN THE CERVICAL CANCER SCREENING PROGRAM IN TAIWAN

    Nov 1, 2010, 00:00

  • PSY47 VARIATION IN PRIMARY CARE CONSULTATION COSTS AMONG NON-CANCER PATIENTS TREATED WITH CHRONIC OPIOID ANALGESIA IN THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PCN103 COST-EFFECTIVENESS ANALYSIS OF ADDING HPV VACCINATION TO CERVICAL CANCER SCREENING PROGRAM IN HUNGARY

    Nov 1, 2010, 00:00

  • PND30 COST-UTILITY ANALYSIS OF LACOSAMIDE ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN EPILEPTIC PATIENTS IN BELGIUM

    Nov 1, 2010, 00:00

  • PIN16 COMPARATIVE CRITICAL REVIEW OF COST-EFFECTIVENESS TOOLS OF PNEUMOCOCCAL CONJUGATE VACCINE (PCV)

    Nov 1, 2010, 00:00

  • PCN156 KNOWLEDGE TRANSFER REGARDING CANCER SCREENING BASED ON INTERESTS OF DIFFERENT TARGET POPULATIONS

    Nov 1, 2010, 00:00

  • DB3 LIFETIME CLINICAL PROJECTIONS FOR OVERWEIGHT OR OBESE SUBJECTS WITH IMPAIRED GLUCOSE INTOLERANCE BASED ON THE LONG TERM RESULTS OF THE DIABETES PREVENTION PROGRAM AND DIABETES PREVENTION PROGRAM OUTCOMES STUDY

    Nov 1, 2010, 00:00

  • PIN34 A CONTINUOUS-TIME ECONOMIC MODEL TO EVALUATE RALTEGRAVIR USE STRATEGIES IN TREATMENT-NAIVE HIV-1 PATIENTS IN PORTUGAL

    Nov 1, 2010, 00:00

  • PMH40 COST-UTILITY ANALYSIS (CUA) OF SERTINDOLE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND IN GENERAL POPULATION OF SCHIZOPHRENIC PATIENTS AND POPULATION OF PATIENTS INTOLERANT TO AT LEAST ONE OTHER ANTIPSYCHOTIC AGENT- A FIVE-YEAR MARKOV ...

    Nov 1, 2010, 00:00

  • PUK9 REAL-LIFE DOSING OF ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN CHRONIC KIDNEY DISEASE (CKD)-ASSOCIATED ANEMIA- BUDGET IMPACT

    Nov 1, 2010, 00:00

  • PDB24 VASCULAR DISEASES AND DURABILITY OF GOOD GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Nov 1, 2010, 00:00

  • PMH44 AN OBSERVATIONAL STUDY OF THE BURDEN OF INFORMAL CAREGIVERS TO OUT-PATIENTS WITH SCHIZOPHRENIA SPECTRUM DISORDERS

    Nov 1, 2010, 00:00

  • PSY9 IMPACT OF CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA AND ITS TREATMENTS ON QUALITY OF LIFE USING THE DELPHI TECHNIQUE

    Nov 1, 2010, 00:00

  • PMH69 INFLUENCE OF WAITING TIME IN A LOCAL MENTAL HEALTH CARE SYSTEM IN GERMANY FOR CARE IN PATIENTS DIAGNOSED WITH SCHIZOPHRENIA OR DEPRESSION

    Nov 1, 2010, 00:00

  • PDB19 HEALTH-RELATED QUALITY OF LIFE AND GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Nov 1, 2010, 00:00

  • PDB33 EVALUATION OF COST AND CLINICAL OUTCOMES BY HBA1C AT DIAGNOSIS USING VARIOUS DIABETES TREATMENT STRATEGIES

    Nov 1, 2010, 00:00

  • PIN7 BUDGET IMPACT MODEL FOR CATCH-UP PROGRAM WITH 13 VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CHILDREN UNDER 5 YEARS OLD IN THE AUTONOMOUS REGION OF MADRID (RM)

    Nov 1, 2010, 00:00

  • PCN90 COMPARATIVE RETROSPECTIVE NON-RANDOMIZED PHARMACOECONOMIC TRIAL OF EFFICIENCY AND SAFETY OF USE OF PACLITAXELS (PACLITAXEL-LENS OR TAXOL) IN A MONOMODE FOR 2ND LINE OF TREATMENT OF METASTATIC BREAST CANCER PATIENTS

    Nov 1, 2010, 00:00

  • PMH61 PRODUCTIVITY LOSS AMONG PATIENTS WITH MOOD DISORDERS

    Nov 1, 2010, 00:00

  • PDB14 HOSPITALIZATION ATTRIBUTED TO DIABETES MELLITUS AND ITS COMPLICATIONS IN THE PRIVATE HEALTH-CARE SYSTEM IN RIBEIRO PRETO REGION, BRAZIL

    Nov 1, 2010, 00:00

  • PCN104 SOCIETAL COST SAVINGS IN METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE

    Nov 1, 2010, 00:00

  • CV1 USING REAL WORLD DATA TO CALCULATE THE COST-EFFECTIVENESS OF STATIN AMONG PARTICIPNATS WITH ATHEROTHROMBOTIC DISEASE IN AUSTRALIAN GENERAL PRACTICE

    Nov 1, 2010, 00:00

  • PSS4 BURDEN OF DISEASE IN PATIENTS WITH GLAUCOMA IN CHINA- RESULTS FFROM 2009 NATIONAL HEALTH AND WELLNESS SURVEY

    Nov 1, 2010, 00:00

  • PCN9 FIRST YEAR MEDICAL CARE COSTS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN A MEDICAID POPULATION

    Nov 1, 2010, 00:00

  • PCV109 SEVENTY-SEVEN HEALTH STATE UTILITIES ESTIMATED IN POLISH CARDIAC PATIENTS

    Nov 1, 2010, 00:00

  • PSS8 PREDICTIVE FACTORS OF GLAUCOMA TREATMENT COST IN GERMANY

    Nov 1, 2010, 00:00

  • PCN154 A COMPARISON OF HTA RECOMMENDATIONS FOR CANCER TREATMENT TECHNOLOGIES PUBLISHED BY AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT (AHTAPOL) AND NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)

    Nov 1, 2010, 00:00

  • PDB50 ASSESSING THE INFLUENCE OF INCORPORATING SECONDARY CARDIOVASCULAR EVENTS INTO A TYPE 2 DIABETES MELLITUS (T2DM) COST-EFFECTIVENESS MODEL

    Nov 1, 2010, 00:00

  • PIN56 REFILL-BASED ADHERENCE RATES OF ANTIRETROVIRAL MEDICATION USING RETROSPECTIVE MEDICINE CLAIMS DATA- A COST ANALYSIS

    Nov 1, 2010, 00:00

  • PHP37 PRIORITIZATION OF HEALTH POLICY AND SYSTEM RESEARCH TOPICS IN THAILAND- MAKING IT SYSTEMATIC, TRANSPARENT AND PARTICIPATORY

    Nov 1, 2010, 00:00

  • PRS50 EMPLOYING MULTI-ATTRIBUTE UTILITY THEORY TO DEVELOP THE EXACT-U-A PREFERENCE-BASED MEASURE FOR COPD EXACERBATION UTILITIES

    Nov 1, 2010, 00:00

  • PCN18 RETROSPECTIVE DATABASE ANALYSIS OF THE EFFECT OF ZOLEDRONIC ACID ON SKELETAL-RELATED EVENTS IN MEN WITH PROSTATE CANCER AND BONE METASTASES

    Nov 1, 2010, 00:00

  • PGI6 COST-EFFECTIVENESS OF MR ELASTOGRAPHY FOR DIAGNOSING LIVER FIBROSIS- PRELIMINARY THRESHOLD ASSESSMENT

    Nov 1, 2010, 00:00

  • PCV127 INCREASING NURSE STAFFING LEVELS IN BELGIAN CARDIAC SURGERY CENTERS- A COST-EFFECTIVE PATIENT SAFETY INTERVENTION?

    Nov 1, 2010, 00:00

  • PIH47 LONG-TERM EFFECTS OF CHILDREN PNEUMOCOCCUS VACCINATION- AN AGENT BASED APPROACH

    Nov 1, 2010, 00:00

  • PIN59 DEVELOPMENT OF A SPECIFIC QUESTIONNAIRE TO ASSESS TREATMENT ADHERENCE OF PATIENTS WITH HCV INFECTION- ADHEPTA STUDY

    Nov 1, 2010, 00:00

  • PCN45 DIFFERENCES IN HEALTH-CARE COSTS FOR PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) TREATED BY ONCOLOGISTS OR UROLOGISTS

    Nov 1, 2010, 00:00

  • PCN51 HOSPITALIZATION COSTS FOR HPV-RELATED CANCERS IN MALES AND FEMALES IN FRANCE

    Nov 1, 2010, 00:00

  • PCV48 COST-OF-ILLNESS AND HEALTH-RELATED QUALITY OF LIFE IN SUBARACHNOID HEMORRHAGE- GERMAN LONGITUDINAL STUDY

    Nov 1, 2010, 00:00

  • PSY3 HEALTH-CARE UTILIZATION AND COST IN PERSONS WITH FACTOR VIII DEFICIENCY- RESULTS OF THE HUGS VA STUDY

    Nov 1, 2010, 00:00

  • DS2 TREND OF ANTIHYPERTENSIVE MEDICATIONS AND RISK OF STROKE AMONG HYPERTENSIVE PATIENTS IN TAIWAN- BASED ON THE NHI DATABASE

    Nov 1, 2010, 00:00

  • PMH60 QUALITY- A NON-INTERVENTIONAL STUDY EVALUATING QUALITY OF LIFE IN SCHIZOPHRENIC PATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS, IN THE AMBULATORY SETTING. A 9-MONTH, OBSERVATIONAL, MULTICENTRIC PROSPECTIVE STUDY

    Nov 1, 2010, 00:00

  • PCV80 THE COST-EFFECTIVENESS OF AMLODIPINE BESYLATE VERSUS PLACEBO FOR THE PREVENTION OF CARDIOVASCULAR DISEASE IN KOREA

    Nov 1, 2010, 00:00

  • PCV49 ESTIMATING THE COST OF ATRIAL FIBRILLATION IN GREECE

    Nov 1, 2010, 00:00

  • PCN5 SOFRAFENIB VERSUS SUNITINIB IN METASTATIC RENAL CELL CARCINOMA- INDIRECT COMPARISON ANALYSIS

    Nov 1, 2010, 00:00

  • PSY51 STATED PREFERENCES OF PHYSICIANS AND CHRONIC PAIN SUFFERERS IN THE USE OF CLASSICAL STRONG OPIOIDS

    Nov 1, 2010, 00:00

  • PMC34 ISSUES IN THE TRANSLATION AND LINGUISTIC VALIDATION OF CAREGIVER RATING SCALES REGARDING THE BEHAVIOR AND DEVELOPMENT OF CHILDREN AND YOUNG PEOPLE

    Nov 1, 2010, 00:00

  • PIH25 PERSPECTIVE OF THAI HEALTH-CARE PROFESSIONALS ON THAI HERBAL MEDICINE POLICY

    Nov 1, 2010, 00:00

  • PMH11 BUDGET IMPACT ANALYSIS OF AMISULPRIDE IN TREATMENT OF SCHIZOPHRENIA IN POLAND

    Nov 1, 2010, 00:00

  • PIN19 HEPATITIS C BURDEN IN RUSSIA

    Nov 1, 2010, 00:00

  • PHP40 REIMBURSEMENT RECOMMENDATION PROCESS IN BRAZIL- CITEC SUBMISSIONS PROFILE

    Nov 1, 2010, 00:00

  • PDB5 IMPROVING PATIENT KNOWLEDGE AND CLINICAL OUTCOMES THROUGH A MEDICATION THERAPY MANAGEMENT (MTM) PROGRAM

    Nov 1, 2010, 00:00

  • PHP109 RELATIVE EFFECTIVENESS ASSESSMENT OF PHARMACEUTICALS

    Nov 1, 2010, 00:00

  • PMH39 THE COST-UTILITY OF AGOMELATINE IN MAJOR DEPRESSIVE DISORDER IN POLAND

    Nov 1, 2010, 00:00

  • PCV75 CANADIAN COST-EFFECTIVENESS ANALYSIS OF DRONEDARONE VERSUS OTHER ANTI-ARRHYTMIC DRUGS IN PATIENTS WITH PAROXYSMAL AND PERSISTENT ATRIAL FIBRILLATION

    Nov 1, 2010, 00:00

  • PCN125 ECONOMIC AND PATIENT-REPORTED OUTCOMES OF OUTPATIENT HOME-BASED VERSUS INPATIENT HOSPITAL-BASED CHEMOTHERAPY FOR PATIENTS WITH COLORECTAL CANCER

    Nov 1, 2010, 00:00

  • HT4 EVIDENCE EXPECTATIONS FROM PAYERS ACROSS THE EU- DOES THE DISEASE BURDEN ON HEALTH-CARE BUDGETS HAVE AN EFFECT?

    Nov 1, 2010, 00:00

  • PCV22 COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN IN PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT IN SLOVAKIA

    Nov 1, 2010, 00:00

  • PHP7 PROSPECTIVE ENCOUNTER STUDY ON PATIENT CARE INDICATORS IN HEALTH-CARE FACILITIES

    Nov 1, 2010, 00:00

  • PND21 COST-EFFECTIVENESS OF TRANSDERMAL PATCH (ROTIGOTINE) IN PATIENTS WITH PARKINSON DISEASE IN MEXICO

    Nov 1, 2010, 00:00

  • PDB23 COST ANALYSIS FOR THE TREATMENT OF DIABETES MELLITUS IN DIFFERENT HEALTH SECTORS OF HEALTH-CARE SYSTEM OF PAKISTAN

    Nov 1, 2010, 00:00

  • PCN91 BEVACIZUMAB S PERSPECTIVE

    Nov 1, 2010, 00:00

  • PCN141 TRANSPARENCY OF DRUG REIMBURSEMENT IN POLAND-ONCOLOGY

    Nov 1, 2010, 00:00

  • PMH56 INNOVATIONS IN COMBINING PATIENT REPORTED OUTCOMES WITH COGNITIVE TESTING DATA TO STREAMLINE AND LEVERAGE REAL-TIME DATA COLLECTION

    Nov 1, 2010, 00:00

  • PCV19 EFFECTIVENESS OF ANTIHYPERTENSIVE AGENTS IN THE SECONDARY PREVENTION OF VASCULAR EVENTS AMONG PATIENTS WITH ISCHEMIC STROKE

    Nov 1, 2010, 00:00

  • PMS28 COST-EFFICACY ANALYSIS OF TNF ALPHA ANTAGONISTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    Nov 1, 2010, 00:00

  • PIH57 CHALLENGES IN THE ADHERENCE AND ADOPTION OF INTERNATIONAL GUIDELINES- A SYSTEMATIC REVIEW OF THE ADHERENCE TO THE HEALTH CARE INFECTION CONTROL PRACTICES ADVISORY COMMITTEE (HICPAC) GUIDELINES FOR THE APPROPRIATE USE OF VANCOMYCIN IN ...

    Nov 1, 2010, 00:00

  • PHP33 CHINESE PAYERS VIEW OF PHARMACEUTICAL VALUE ATTRIBUTES- WHICH EVIDENCE DRIVES ACCESS?

    Nov 1, 2010, 00:00

  • PIN23 BELIEFS ABOUT THE USE OF NONPRESCRIBED ANTIBIOTICS AMONG INDONESIAN PEOPLE-A PRELIMINARY STUDY IN YOGYAKARTA CITY INDONESIA

    Nov 1, 2010, 00:00

  • PIH10 TREATMENT AND COST FOR PATIENTS WITH ENDOMETRIOSIS IN THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PCV10 COST SAVINGS OF SINGLE PILL AMLODIPINE/ATORVASTATIN THERAPY IN HYPERTENSION AND DYSLIPIDEMIA PATIENTS IN CHINA

    Nov 1, 2010, 00:00

  • MA1 HOW TO HANDLE THE MAPPING PROBLEM IN COST-UTILITY ANALYSES?

    Nov 1, 2010, 00:00

  • PDB52 LONG-TERM COST-EFFECTIVENESS OF LIRAGLUTIDE VS. ROSIGLITAZONE IN THE CZECH REPUBLIC

    Nov 1, 2010, 00:00

  • PIH17 GENERAL PUBLIC SATISFACTION TOWARD THE PROVISION OF HEALTH-CARE DELIVERY BY GOVERNMENT HOSPITALS AND CLINICS IN THE STATE OF PENANG

    Nov 1, 2010, 00:00

  • PHP108 CLINICAL EVIDENCE REQUIREMENTS- COMPARISON BETWEEN SEVEN HTA AGENCIES AND IMPLICATIONS FOR DRUG MANUFACTURERS

    Nov 1, 2010, 00:00

  • PIN40 COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION AMONG INFANTS IN RUSSIA- ECONOMIC EVALUATION OF THE PNEUMOCOCCAL 7-VALENT CONJUGATE VACCINE

    Nov 1, 2010, 00:00

  • MO3 THE DEVELOPMENT AND VALIDATION OF A DECISION MODEL REPRESENTING THE FULL DISEASE COURSE OF ACUTE MYELOID LEUKEMIA

    Nov 1, 2010, 00:00

  • PHP39 THE EFFECTS OF DIRECT BILLING SYSTEM IN PATIENTS WITH CIVIL-SERVANT MEDICAL BENEFIT SCHEMES ON PRESCRIBING PATTERNS

    Nov 1, 2010, 00:00

  • PMC16 HOW DO THIN DEATH DATA COMPARE TO NATIONAL FIGURES FOR EACH UK COUNTRY?

    Nov 1, 2010, 00:00

  • PCV50 THE COST OF ATRIAL FIBRILLATION IN SWEDEN

    Nov 1, 2010, 00:00

  • PMC30 COGNITIVE DEBRIEFING METHODS IN TRANSLATION OF PROS-A MULTI-NATIONAL

    Nov 1, 2010, 00:00

  • PRS31 SHOULD SALMETEROL/FLUTICASONE PROPIONATE (SAL/FP) BE ADDED TO ROUTINE COPD TREATMENT WITH FENOTEROL/ IPRATROPIUM BROMIDE (FEN/IB)? PHARMACOECONOMIC ASSESSMENT OF COPD TREATMENT BASED ON OBSERVATIONAL RESEARCH (PHACTOR)

    Nov 1, 2010, 00:00

  • PMH7 USING DRUG DISPENSING DATA TO STUDY THE VALIDITY OF PARASKAVEDEKATRIAPHOBIA

    Nov 1, 2010, 00:00

  • PHP23 ECONOMIC EVALUATION OF TELEHEALTH/TELEMEDICINE AND COST-EFFECTIVENESS ARGUMENT AMONG KEY DECISION-MAKERS

    Nov 1, 2010, 00:00

  • PCN37 GAUGING THE ROLE OF HTA IN REIMBURSEMENT DECISION-MAKING ACROSS SEVEN MARKETS IN ASIA-PACIFIC

    Nov 1, 2010, 00:00

  • PCV71 IS COREVALVE A COST-EFFECTIVE TREATMENT FOR PATIENTS WITH SEVERE AORTIC STENOSIS WHO SATISY ALL THE CRITERIA FOR CONVENTIONAL AORTIC VALVE REPLACEMENT?

    Nov 1, 2010, 00:00

  • MA4 ANCHOR-BASED DETERMINATION OF THE MINIMAL IMPORTANT DIFFERENCE OF A PRO SCALE-A CRITICAL LOOK ON A WIDELY USED METHOD BY MEANS OF A SIMULATION STUDY

    Nov 1, 2010, 00:00

  • PIH48 ANTIDEPRESSANT PRESCRIBING TO PATIENTS AGED 18 YEARS AND YOUNGER- A PHARMACOEPIDEMIOLOGICAL STUDY

    Nov 1, 2010, 00:00

  • PCV102 ASSOCIATION BETWEEN KNOWLEDGE AND DRUG ADHERENCE IN PATIENTS WITH HYPERTENSION IN QUETTA, PAKISTAN

    Nov 1, 2010, 00:00

  • PSY59 ACCESSIBILITY AND UTILIZATION OF BORTEZOMIB IN DUTCH DAILY PRACTICE

    Nov 1, 2010, 00:00

  • PMH6 MEASURING THE COST OF ILLNESS RELATED ALCOHOL IN KOREA

    Nov 1, 2010, 00:00

  • PSY5 A MARKOV MODEL TO ESTIMATE THE EFFECT OF CANAKINUMAB ON THE PROGRESSION OF AA AMYLOIDOSIS IN PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC-FEVER SYNDROMES (CAPS)

    Nov 1, 2010, 00:00

  • PHP61 MARKET ACCESS AGREEMENTS IN EUROPE-TYPOLOGY AND RATIONALE

    Nov 1, 2010, 00:00

  • PHP17 MEASURING MEDICATION RECONCILIATIONS IMPACT ON THE FINANCIAL COST

    Nov 1, 2010, 00:00

  • PND2 THE INFLUENCE OF PARENTERAL NUTRITION ON THE PLASMA PROTEIN BINDING OF THERAPEUTIC DRUGS

    Nov 1, 2010, 00:00

  • PGI29 PPI GENERAL PRACTITIONERS PRESCRIBING IN THE TREATMENT OF ACID-RELATED DISORDERS-THE IMPACT OF GENERIC PPI LAUNCH INTO THE PHARMACEUTICAL MARKET IN ITALY

    Nov 1, 2010, 00:00

  • PND6 VALUE OF BUDGET IMPACT ANALYSIS BASED ON EPIDEMIOLOGIC DATA- INSIGHTS FROM MULTIPLE SCLEROSIS IN SAO PAULO, BRAZIL

    Nov 1, 2010, 00:00

  • PMS32 MICRO-COSTING ANALYSIS AND TARIFF COMPARISON- THE INTERSPINOUS PROCESS DEVICE CASE

    Nov 1, 2010, 00:00

  • IR4 HUNTINGTON QUALITY OF LIFE INTERVIEW (HQOLI)- A NEW HUNTINGTONS DISEASE-SPECIFIC QUALITY OF LIFE INSTRUMENT

    Nov 1, 2010, 00:00

  • PCN1 THE EVALUATION OF ADR ONLINE REPORTING OF RADIOPAQUE AGENTS IN A UNIVERSITY HOSPITAL IN TAIWAN

    Nov 1, 2010, 00:00

  • PMH5 A DIRECT MEDICAL COST ANALYSIS OF GEROPSYCHIATRIC PATIENTS IN TAIWAN

    Nov 1, 2010, 00:00

  • PCV39 CLINICAL OUTCOMES AND COSTS OF A POCKET-SIZED ULTRASOUND DEVICE FOR SCREENING FOR ABDOMINAL AORTIC ANEURYSM IN ITALY

    Nov 1, 2010, 00:00

  • BL2 PATIENT PREFERENCES FOR BIOLOGIC AGENTS IN RHEUMATOID ARTHRITIS- A DISCRETE CHOICE EXPERIMENT

    Nov 1, 2010, 00:00

  • PMC10 RELIABILITY OF MANUFACTURERS BUDGET IMPACT ESTIMATES IN POLAND

    Nov 1, 2010, 00:00

  • PCN77 COST-EFFECTIVENESS OF OCTREOTIDE LAR IN PATIENTS WITH METASTATIC NEUROENDOCRINE MIDGUT TUMORS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2010, 00:00

  • PGI23 IDENTIFYING ENDPOINTS FOR IRRITABLE BOWEL SYNDROME (IBS) CLINICAL TRIALS- INCORPORATING THE PATIENTS VOICE

    Nov 1, 2010, 00:00

  • PHP21 EARLY ACCESS- ANALYSIS OF THE FRENCH ATU SYSTEM

    Nov 1, 2010, 00:00

  • PHP28 THE COLLECTION AND USE OF 'REAL WORLD' DATA- INDUSTRY VIEWS

    Nov 1, 2010, 00:00

  • PIH14 COST-BENEFIT OF FLUCONAZOLE FOR VAGINAL CANDIDIASIS

    Nov 1, 2010, 00:00

  • PCV32 COST-EFFECTIVENESS ANALYSIS OF DISEASE MANAGEMENT PROGRAM OF HYPERTENSION IN SHANGHAI, CHINA

    Nov 1, 2010, 00:00

  • PHP99 FIRST-IN-THERAPY PRODUCTS AND REQUIREMENTS FOR SUCCESSFUL HTA ASSESSMENT

    Nov 1, 2010, 00:00

  • PCV74 ONE-YEAR COST-EFFECTIVENESS OF CYTOCHROME P450 2C19 GENOTYPE-GUIDED ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROMES IN THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • ISPOR 4TH ASIA-PACIFIC CONFERENCE DISCLOSURE INFORMATION

    Nov 1, 2010, 00:00

  • CV2 ATTRIBUTABLE COST AND LENGTH OF STAY FOR PATIENTS WITH ENOXAPARIN-ASSOCIATED BLEEDING

    Nov 1, 2010, 00:00

  • PSS18 ECONOMIC EVALUATION OF A 100 WHEY-BASED, PARTIALLY HYDROLYZED INFANT FORMULA IN THE PREVENTION OF ATOPIC DERMATITIS AMONG SPANISH CHILDREN

    Nov 1, 2010, 00:00

  • PMC44 EXPERTS JUDGEMENT ON PATIENT-CENTRED COORDINATED CARE

    Nov 1, 2010, 00:00

  • PHP32 EFFECTIVENESS OF ANTIBACTERIAL THERAPY OPTIMIZATION BY CLINICAL PHARMACOLOGISTS

    Nov 1, 2010, 00:00

  • PGI3 EFFECTIVENESS AND COST ANALYSIS OF PARENTERNAL REGIMEN IN CRITICAL ILLNESS PATIENTS OF POSTOPERATIVE-THREE COMPARTMENT BAG SYSTEM AND TRANDITIONAL SEPARATE BOTTLE SYSTEM

    Nov 1, 2010, 00:00

  • PIN77 DO WE ADEQUATELY MODEL THE BENEFIT OF ROTAVIRUS VACCINATION OVER TIME?

    Nov 1, 2010, 00:00

  • PCN37 BI OF IRESSA IN NSCLC IN THE NETHERLANDS-A HOSPITAL PERSPECTIVE

    Nov 1, 2010, 00:00

  • PIN52 AN ECONOMIC EVALUATION OF RALTEGRAVIR FOR THE TREATMENT OF ANTIRETROVIRAL-NAIVE HIV-1 INFECTED PATIENTS IN HUNGARY

    Nov 1, 2010, 00:00

  • PCN111 HEALTH-CARE RESOURCE UTILIZATION IN ADVANCED MELANOMA- AN ANALYSIS FROM THE MELODY OBSERVATIONAL STUDY

    Nov 1, 2010, 00:00

  • PRS18 HEALTH CARE COSTS OF INDIVIDUALS WITH AND WITHOUT COPD IN SWEDEN

    Nov 1, 2010, 00:00

  • PMH25 COMPARISON OF ESCITALOPRAM VS. CITALOPRAM AND VENLAFAXINE IN THE TREATMENT OF MAJOR DEPRESSION IN SPAIN- CLINICAL AND ECONOMIC CONSEQUENCES

    Nov 1, 2010, 00:00

  • PUK23 ECONOMIC EVALUATION OF DIFFERENT TREATMENT MODALITIES IN ACUTE KIDNEY INJURY

    Nov 1, 2010, 00:00

  • PIN4 SURGICAL SITE INFECTION IN JAPAN-A SYSTEMATIC REVIEW OF THE INCIDENCE AND ECONOMIC BURDEN

    Nov 1, 2010, 00:00

  • PIN4 IMPACT OF MMRV MASS VACCINATION WITH OR WITHOUT A CATCH UP PROGRAM ON THE INCIDENCE OF VARICELLA COMPLICATIONS IN FRANCE

    Nov 1, 2010, 00:00

  • PMC19 THE THRESHOLD PRICING MODEL- NOT JUST ANOTHER COSTEFFECTIVENESS MODEL

    Nov 1, 2010, 00:00

  • HT4 HEALTH TECHNOLOGY ASSESSMENT DATABASE IN THAILAND

    Nov 1, 2010, 00:00

  • PGI20 MEDICATION ADHERENCE AND PERSISTENCE IN THE TREATMENT OF ULCERATIVE COLITIS- ANALYSES WITH THE RAMQ DATABASE

    Nov 1, 2010, 00:00

  • PCV5 COMPARISON OF ADVERSE EVENTS OF MEDICARE PATIENTS WHO UNDERWENT KNEE REPLACEMENT SURGERY AND EXPERIENCED VENOUS THROMBOEMBOLISM VERSUS NO VENOUS THROMBOEMBOLISM

    Nov 1, 2010, 00:00

  • AD2 THE SOCIETAL BURDEN OF POOR PERSISTENCE TO TREATMENT OF OSTEOPOROSIS IN SWEDEN

    Nov 1, 2010, 00:00

  • PIH22 EVALUATING THE COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING AND HUMAN PAPILLOMAVIRUS VACCINATION STRATEGIES USING A MATHEMATICAL MODEL

    Nov 1, 2010, 00:00

  • PSS8 COST-EFFECTIVENESS OF BRINZOLAMIDE/TIMOLOL FIXED COMBINATION (BTFC) VERSUS DORZOLAMIDE/TIMOLOL FIXED COMBINATION (DTFC) FOR PATIENTS WITH OPEN ANGLE GLAUCOMA IN KOREA AND TAIWAN

    Nov 1, 2010, 00:00

  • PND4 BUDGET IMPACT ANALYSIS OF NATALIZUMAB FOR MULTIPLE SCLEROSIS TREATMENT IN BRAZIL- A 5-YEAR PROJECTION

    Nov 1, 2010, 00:00

  • PGI7 ECONOMIC BURDEN OF OPIOID INDUCED CONSTIPATION IN SPAIN

    Nov 1, 2010, 00:00

  • PCV62 UPTAKE AND COSTS OF IMAGING MODALITIES IN PACEMAKERIMPLANTED AND NON-IMPLANTED PATIENTS

    Nov 1, 2010, 00:00

  • PDB10 PREVALENCE AND OUTCOME OF INSULIN ANALOGUE TREATMENT COMPARING GERMANY, UK, AND FRANCE

    Nov 1, 2010, 00:00

  • PDB88 LEARNING FROM DISEASE MANAGEMENT PROGRAMMES- HOW MEDICAL TREATMENTS AND QUALITY OF DIABETIC CARE (TYPE II) IN GERMANY ARE DIRECTLY AND INDIRECTLY IMPROVED BY DMPS

    Nov 1, 2010, 00:00

  • PDB12 COST-EFFECTIVENESS ANALYSIS OF GLIMEPIRIDE OR PIOGLITAZONE IN COMBINATION WITH METFORMIN IN TYPE-II DIABETIC PATIENTS IN KOREA

    Nov 1, 2010, 00:00

  • PDB3 EFFICACY AND SAFETY OF DIPEPTIDYL-PEPTIDASE 4 [DPP 4] INHIBITORS IN TYPE 2 DIABETES- META-ANALYSIS

    Nov 1, 2010, 00:00

  • BI1 ANALYZING OVERALL SURVIVAL IN RANDOMIZED CONTROLLED TRIALS WITH CROSS-OVER

    Nov 1, 2010, 00:00

  • PCN14 ADDITIONAL HEALTH AND ECONOMIC IMPACT OF THE BIVALENT VERSUS THE QUADRIVALENT HPV VACCINE IN TAIWAN- RESULTS OF A PREVALENCE-BASED MODEL

    Nov 1, 2010, 00:00

  • PMH18 THE COSTS OF DEPRESSION IN SWITZERLAND

    Nov 1, 2010, 00:00

  • PHP19 THE COST OF ILLNESS IN KOREA (2007)

    Nov 1, 2010, 00:00

  • PIN12 PSEUDOMONAS AERUGINOSA RELATED BURDEN ON CYSTIC FIBROSIS PATIENTS- COMPARING HEALTH CARE COSTS AND RESOURCE UTILIZATION ACROSS AGE GROUPS

    Nov 1, 2010, 00:00

  • PDB11 DRUG-USE PATTERNS OF INITIALLY PRESCRIBED INSULIN DETEMIR AND INSULIN GLARGINE IN THE NETHERLANDS;A COMPARATIVE ANALYSIS USING PHARMACY DATA FROM IADB. NL

    Nov 1, 2010, 00:00

  • PCV67 COST-EFFECTIVENESS OF FONDAPARINUX VS. ENOXAPARIN IN NON-ST-ELEVATION ACUTE CORONARY SYNDROMES IN RUSSIA

    Nov 1, 2010, 00:00

  • PHP73 CONTENT OF HOME PHARMACIES IN SERBIA

    Nov 1, 2010, 00:00

  • PND45 MANAGEMENT OF DRUG RESISTANT EPILEPSIES- HTA REPORT FOR THREE ITALIAN REGIONS

    Nov 1, 2010, 00:00

  • PCV115 ASSESSMENT OF THE ASSOCIATION BETWEEN SUMMARY SYMPTOM MEASURES AND HEALTH STATUS OF PATIENTS WITH ISCHEMIC HEART DISEASE

    Nov 1, 2010, 00:00

  • CN3 QUALITY OF LIFE IN ADVANCED CANCER PATIENT-COMPARISON OF PATIENT-REPORTED OUTCOME (PRO) AND PROXIES ASSESSMENT

    Nov 1, 2010, 00:00

  • PIH55 BPH PATIENTS TREATED WITH PHYTOTHERAPY- RESULTS AT 6 MONTHS

    Nov 1, 2010, 00:00

  • PSY37 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF OROS HYDROMORPHONE IN PATIENTS WITH CHRONIC CANCER PAIN FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2010, 00:00

  • PDB48 COST-EFFECTIVENESS OF 2 DIABETES HEALTH CARE PROGRAMMES IN BELGIUM

    Nov 1, 2010, 00:00

  • PSS9 SUMMARIZING UTILITY VALUES OF PATIENTS WITH AGE-RELATED MACULAR DEGENERATION-A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2010, 00:00

  • IR2 SCALING PROPERTIES OF TWO COMMONLY USED OUTCOME MEASURES IN DERMATOLOGY-THE DERMATOLOGY LIFE QUALITY INDEX (DLQI) AND THE PSORIASIS QUALITY OF LIFE SCALE (PSORIQOL)

    Nov 1, 2010, 00:00

  • PHP78 A TALE OF FOUR COUNTRIES- COMPARING REIMBURSEMENT SUBMISSION REQUIREMENTS IN IRELAND, ENGLAND, WALES AND SCOTLAND

    Nov 1, 2010, 00:00

  • PDB75 THE IMPACT OF PERCEPTIONS OF WEIGHT ON OVERALL HEALTHRELATED WELL-BEING IN EUROPEAN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)

    Nov 1, 2010, 00:00

  • PSY23 COST OF POMPE DISEASE IN POLAND IN 2008 AND 2009

    Nov 1, 2010, 00:00

  • PCN6 RISK OF BREAST CANCER AMONG USERS OF POSTMENOPAUSAL HORMONE REPLACEMENT THERAPY IN TAIWAN

    Nov 1, 2010, 00:00

  • PCV20 GENERALIZED COST-EFFECTIVENESS ANALYSIS OF PHARMACEUTICAL INTERVENTIONS FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN THAILAND

    Nov 1, 2010, 00:00

  • PSY8 BUDGET IMPACT OF THE USE OF HYDROMORPHONE ONCE DAILY IN CHRONIC PAIN PATIENTS IN THE GERMAN HEALTH CARE SYSTEM-AN UPDATE

    Nov 1, 2010, 00:00

  • PMH73 IMPACT OF PLACEBO RUN-IN PERIOD ON RELATIVE TREATMENT EFFECT IN GENERALIZED ANXIETY DISORDER (GAD)

    Nov 1, 2010, 00:00

  • PDB93 THE RELIABILITY OF PROPORTION OF DAYS COVERED CALCULATIONS USING DEFINED DAILY DOSE ESTIMATES

    Nov 1, 2010, 00:00

  • PMH29 COST-CONSEQUENCE ANALYSIS OF ARIPIPRAZOLE IN SCHIZOPHRENIA IN SPAIN- DIABETES AND CORONARY HEART DISEASE PROJECTIONS (STAR STUDY)

    Nov 1, 2010, 00:00

  • PCN32 USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE MARGINAL WILLINGNESS TO PAY OF INSURANCE PREMIUM FOR STOMACH CANCER TREATMENT IN KOREA

    Nov 1, 2010, 00:00

  • PCN11 GEFITINIB COMPARED WITH DOUBLET CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC)- A SYSTEMATIC REVIEW AND ADJUSTED INDIRECT COMPARISON

    Nov 1, 2010, 00:00

  • PIH63 TURKISH CULTURAL ADAPTATION AND VALIDATION OF GLASGOW HEALTH STATUS INVENTORY

    Nov 1, 2010, 00:00

  • CN3 COST OF ABSENTEEISM DUE TO CANCER IN POLAND

    Nov 1, 2010, 00:00

  • PIH42 THE USE OF PATIENT-REPORTED OUTCOME MEASURES FOR DRUG APPROVAL IN KOREA

    Nov 1, 2010, 00:00

  • PMC39 EXAMINING ITEM RESPONSE PATTERNS OVER TIME IN A HEALTH PROFILE MEASURE USING US NATIONAL REPRESENTATIVE SAMPLES- A MULTI-FACET MODEL APPROACH

    Nov 1, 2010, 00:00

  • PMC41 PREEMPTING DIFFICULTIES IN LINGUISTIC VALIDATION, THE USE OF FACE VALIDATION TO CREATE MORE SOUND TRANSLATIONS

    Nov 1, 2010, 00:00

  • PMS66 PENETRATION OF MONOCLONAL ANTIBODIES ONTO FINNISH PHARMACEUTICAL MARKET

    Nov 1, 2010, 00:00

  • EQ1 PSYCHOMETRIC COMPARISON OF EQ-5D AND EQ-5D-5L IN STUDENT POPULATION

    Nov 1, 2010, 00:00

  • PCN43 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN ITALY

    Nov 1, 2010, 00:00

  • PCV9 POTENTIAL COST SAVINGS OF SMOKING CESSATION WITH VARENICLINE AMONG INSURED CHINESE POPULATION

    Nov 1, 2010, 00:00

  • RS1 A RISK FORECASTING MODEL TO HELP IN THE DESIGNING OF RISK-SHARING SCHEMES

    Nov 1, 2010, 00:00

  • PMS27 ANALYSIS OF DIRECT MEDICAL AND NON-MEDICAL COSTS FOR CARE OF RHEUMATOID ARTHRITIS PATIENTS USING LARGE COHORT DATABASE, IORRA

    Nov 1, 2010, 00:00

  • PGI9 HOSPITAL COST FOR TREATMENT OF PATIENTS WITH PEPTIC ULCER BLEED (PUB) IN SWEDEN-DATA FROM THE KPP (COST PER PATIENT) DATABASE

    Nov 1, 2010, 00:00

  • PDB35 COST-CONSEQUENCE ANALYSIS OF CSII VS. MDI-A CANADIAN PERSPECTIVE

    Nov 1, 2010, 00:00

  • PDB13 THE IMPACT OF BEING AT-RISK FOR DIABETES IN CHINA AND THE UNITED STATES

    Nov 1, 2010, 00:00

  • PIN33 THE POTENTIAL PUBLIC HEALTH BENEFIT OF PNEUMOCOCCAL CONJUGATE VACCINES- EXAMPLE OF THE CZECH REPUBLIC

    Nov 1, 2010, 00:00

  • PDB5 TOTAL AND DIABETES-RELATED COSTS ASSOCIATED WITH HYPOGLYCEMIA IN TYPE 2 DIABETES MELLITUS PATIENTS INITIATED ON ORAL ANTIDIABETIC DRUGS FROM A LARGE US MANAGED CARE COHORT

    Nov 1, 2010, 00:00

  • PIH29 RETROSPECTIVE EVALUATION OF THE IMPACT OF COST-SHARE INCREASES FOR SPECIALTY MEDICATIONS ON ADHERENCE AND PERSISTENCE

    Nov 1, 2010, 00:00

  • PSS37 CATARACT SURGERY GUIDELINES IN EUROPE- A LITERATURE REVIEW AND DOCUMENT SEARCH IN 15 COUNTRIES

    Nov 1, 2010, 00:00

  • PCN24 A POPULATION-BASED DECISION ANALYTIC MODEL FOR ASSESSING THE HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM

    Nov 1, 2010, 00:00

  • PDB82 PRESCRIBED DAILY DOSES OF ONCE-DAILY LIRAGLUTIDE IN THE GERMAN STATUTORY HEALTH INSURANCE (SHI)

    Nov 1, 2010, 00:00

  • PCV70 COST SAVINGS OF ENOXAPARIN OVER UFH IN MEDICAL PATIENTS IN CANADIAN HOSPITAL SETTING

    Nov 1, 2010, 00:00

  • PND38 DIFFICULTIES IN IDENTIFYING THE ORIGINAL SOURCE QUESTIONNAIRE FOR USE IN TRANSLATIONS- THE ADAS-COG CASE STUDY

    Nov 1, 2010, 00:00

  • PND28 COST-UTILITY ANALYSIS OF ROTIGOTINE TRANSDERMAL PATCH IN EARLY-STAGE PARKINSONS DISEASE IN SCOTLAND

    Nov 1, 2010, 00:00

  • PCN153 HOW DO HTA AGENCIES RECOGNIZE AND REWARD INNOVATION? CASE STUDIES IN BREAST CANCER AND COLORECTAL CANCER

    Nov 1, 2010, 00:00

  • PCV140 HOSPITAL QUALITY INDEX AND ITS USE ON RATES OF VENOUS THROMBOEMBOLISM

    Nov 1, 2010, 00:00

  • PRS6 BURDEN OF SMOKING RELATED MAJOR DISEASES IN INDIA- ESTIMATION OF DIRECT OUT-OF-POCKET COST

    Nov 1, 2010, 00:00

  • PIH15 SENSITIVITY OF GENERIC PATIENT-REPORTED OUTCOMES MEASURES AMONG CAREGIVERS OF CHILDREN WITH CRANIOFACIAL MALFORMATION

    Nov 1, 2010, 00:00

  • PSS5 COST OF GLAUCOMA IN THE UNITED KINGDOM ACCORDING TO THE UK GPRD

    Nov 1, 2010, 00:00

  • PIN78 ECONOMIC IMPACT OF INFLUENZA EPIDEMICS- MODELLING INTERACTIONS OF INFECTIONS, TREATMENT PATHWAYS AND REIMBURSEMENT

    Nov 1, 2010, 00:00

  • PGI24 A PILOT STUDY OF PATIENT PREFERENCES FOR MID-THERAPY ASSESSMENT TIMING IN CHRONIC HEPATITIS C TREATMENT

    Nov 1, 2010, 00:00

  • PCN166 DEVELOPMENT OF A FLAG SYSTEM FOR THE COMPUTERIZED DETECTION OF CANCER PATIENTS WITH ADDITIONAL TREATMENT NEEDS BY MEANS OF THE 'COMPUTER BASED HEALTH EVALUATION SYSTEM' (CHES)

    Nov 1, 2010, 00:00

  • PDB4 A CROSS-SECTIONAL STUDY ON GLYCEMIC CONTROL AND ADVERSE EVENTS IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH ORAL ANTIDIABETIC DRUGS IN CHINA

    Nov 1, 2010, 00:00

  • PIH59 PUBLIC HEALTH ECONOMICS-AN EMERGENT SUBDISCIPLINE?

    Nov 1, 2010, 00:00

  • PIH12 COST UTILITY ANALYSIS OF HPV VACCINATION WITH BIVALENT AS04 ADJUVANT VACCINE IN SLOVAKIA AND IMPACT OF VACCINE PROTECTION DURATION ON COST-EFFECTIVENESS ENDPOINTS

    Nov 1, 2010, 00:00

  • PDB25 DIABETES-RELATED COMPLICATIONS AND GLYCEMIC CONTROL IN TYPE 2 DIABETIC MELLITUS PATIENTS AT SPECIALIST OUTPATIENT CLINICS IN SINGAPORE

    Nov 1, 2010, 00:00

  • CN4 CAN WE CORRECTLY TARGET HIGH-COST THERAPIES? THE DIAGNOSTIC ACCURACY OF HISTOLOGY IN DIFFERENTIATING BETWEEN SQUAMOUS AND NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

    Nov 1, 2010, 00:00

  • PCV64 COST CONSEQUENCES AND RESOURCE UTILIZATION IN TRANSCATETHER AORTIC VALVE IMPLANTATION (TAVI) AS A SUBSTITUTION FOR HIGH RISK SURGICAL PATIENTS

    Nov 1, 2010, 00:00

  • PMS30 MEDICINE TREATMENT COST OF RHEUMATOID ARTHRITIS BEFORE AND AFTER TREATMENT WITH BIOLOGICAL DRUGS

    Nov 1, 2010, 00:00

  • PSY13 COST IMPACT FROM INITIATING PREGABALIN TREATMENT IN PATIENTS WITH REFRACTORY NEUROPATHIC PAIN

    Nov 1, 2010, 00:00

  • PMS38 COST-EFFECTIVENESS OF RITUXIMAB VERSUS ALTERNATIVE ANTI-TUMOR NECROSIS FACTOR (TNF) THERAPY AFTER PREVIOUS FAILURE OF ONE ANTI-TNF AGENT FOR TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO

    Nov 1, 2010, 00:00

  • PRS9 QUALITY OF LIFE AND ECONOMIC IMPACT OF ASTHMA CONTROL IN FRANCE AND SPAIN. FIRST RESULTS OF THE EU-COAST STUDY

    Nov 1, 2010, 00:00

  • PIN31 PHARMACOECONOMIC MODELING USING THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN GERMAN ADULTS

    Nov 1, 2010, 00:00

  • PCV133 PRACTICE PATTERNS AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2008-2009- BASELINE RESULTS FOR GERMANY FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR II)

    Nov 1, 2010, 00:00

  • PCV110 HOW PATIENTS EXPERIENCE COULD INFLUENCE THEIR PREFERENCES TOWARD TREATMENT FOR ABDOMINAL AORTIC ANEURYSM- RESULTS FROM THE PREFER STUDY

    Nov 1, 2010, 00:00

  • PMS71 INDIRECT TREATMENT COMPARISON TO COMPARE EFFICACY IN HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) SCORE FOR BIOLOGIC AGENTS WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ACTIVE DISEASE DESPITE METHOTREXATE THERAPY

    Nov 1, 2010, 00:00

  • PRS11 COST ANALYSIS OF DIFFERENT PHARMACOTHERAPIES IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE PUBLIC SECTOR OF HONG KONG

    Nov 1, 2010, 00:00

  • PMC36 SYSTEMATIC REVIEW OF THE RESPONSIVNESS OF SF-36 HEALTH SURVEY MEASURES TO EFFICACIOUS PHARMACEUTICAL THERAPIES IN WELL-CONTROLLED CLINICAL TRIALS

    Nov 1, 2010, 00:00

  • PIH18 COST-EFFECTIVENESS OF COMBINATION THERAPY WITH DUTASTERIDE AND TAMSULOSIN FOR THE TREATMENT OF MODERATE TO SEVERE BENIGN PROSTATIC HYPERPLASIA IN SPAIN

    Nov 1, 2010, 00:00

  • PCV113 HEALTH-RELATED QUALITY OF LIFE OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION COMPARED TO HEALTHY SUBJECTS IN HONG KONG

    Nov 1, 2010, 00:00

  • PHP55 INVESTIGATING THE IMPACT OF RD INVESTMENT AND POLICY ON INNOVATIVE PERFORMANCE IN EUROPE

    Nov 1, 2010, 00:00

  • PND22 COST-EFFECTIVENESS ANALYSIS COMPARING BRIDION (SUGAMMADEX) WITH NEOSTIGMIN AND SPONTANEOUS RECOVERY IN THE REVERSAL OF NEUROMUSCULAR BLOCKADE INDUCED BY ROCURONIUM/VECURONIUM

    Nov 1, 2010, 00:00

  • PSY11 COSTS OF SUPPORTIVE CARE (SC) FOR THE TREATMENT OF MYELODISPLASTIC SYNDROME (MDS) IN BRAZIL- AN ANALYSIS FROM THE PRIVATE PAYERS PERSPECTIVE

    Nov 1, 2010, 00:00

  • PCN114 VISITING DOCTORS WITH MALIGNANT MELANOMA

    Nov 1, 2010, 00:00

  • PCN6 PRESERVED ANTITUMOR ACTIVITY AND REDUCED CARDIOTOXICITY OF FIRST-LINE PEGYLATED LIPOSOMAL DOXORUBICIN COMPARED WITH CONVENTIONAL DOXORUBICIN IN PATIENTS WITH METASTATIC BREAST CANCER

    Nov 1, 2010, 00:00

  • PRS26 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF MOMETASONE FUROATE AS MAINTENANCE TREATMENT IN PATIENTS WITH MILD TO MODERATE ASTHMA FROM THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2010, 00:00

  • PCV30 PERCEPTION OF PATIENTS ON WARFARIN THERAPY TOWARD PHARMACIST-MANAGED ANTICOAGULATION SERVICE IN AMBULATORY CARE SETTINGS IN SINGAPORE

    Nov 1, 2010, 00:00

  • MO2 HERD IMMUNITY AS A RESULT IN DYNAMIC AGENT-BASED EPIDEMIC MODELS

    Nov 1, 2010, 00:00

  • PIH23 COST-EFFECTIVENESS ANALYSIS OF 5-ALPHA REDUCTASE INHIBITORS IN PATIENTS WITH BPH AND AN ELEVATED PSA IN SWEDEN

    Nov 1, 2010, 00:00

  • PUK15 RESOURCE USE AND COSTS OF PATIENTS UNDERGOING DIALYSIS IN BELGIUM

    Nov 1, 2010, 00:00

  • PCN67 MANAGEMENT OF MALIGNANT ASCITES IN GERMANY-TREATMENT PATTERNS, RESOURCE CONSUMPTION, AND COSTS

    Nov 1, 2010, 00:00

  • PGI26 PREVALENCE AND IMPACT IN WORK PRODUCTIVITY OF GASTROESOFAGEAL REFLUX DISEASE (GERD) IN PRIMARY CARE PATIENTS WITH UPPER GASTROINTESTINAL (GI) SYMPTOMS. THE GREEK GERDQ STUDY

    Nov 1, 2010, 00:00

  • PMS17 BUDGET IMPACT OF NEW RHBMP-2 FORMULATION IN PATIENTS UNDERGOING POSTEROLATERAL SPINAL FUSION PROCEDURES FOR DEGENERATIVE DISC DISEASE IN RANDOMIZED CONTROLLED TRIAL (RCT)

    Nov 1, 2010, 00:00

  • PSS5 HEALTH RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION IN THAILAND- PRELIMINARY FINDINGS

    Nov 1, 2010, 00:00

  • PIH17 COST-EFFECTIVENESS OF SEASONAL INFLUENZA VACCINATION IN PREGNANCY IS DEPENDENT ON VACCINATION EARLY IN FLU SEASON

    Nov 1, 2010, 00:00

  • PDB89 PREDICTORS OF ROUTINE MONITORING OF DIABETES CARE AMONG THE US NON-INSTITUTIONALIZED POPULATION- A RETROSPECTIVE ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS) IN 2007

    Nov 1, 2010, 00:00

  • PIN21 COST-EFFECTIVENESS OF DAPTOMYCIN IN PATIENTS WITH INFECTIVE ENDOCARDITIS AND BACTEREMIA CAUSED BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS IN TURKEY

    Nov 1, 2010, 00:00

  • PDB26 ECONOMIC BURDEN OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY IN KOREA

    Nov 1, 2010, 00:00

  • PMS43 COST-UTILITY AND MULTINOMIAL EXPECTED VALUE OF PERFECT INFORMATION OF SEQUENCED TREATMENT WITH BIOLOGICS IN MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS- ANALYSIS BASED ON CLINICALLY MEANINGFUL RESPONSES

    Nov 1, 2010, 00:00

  • PHP134 IMPACT OF BLEEDING-RELATED CONSEQUENCES ON LENGTH OF STAY (LOS) AND HOSPITAL COSTS IN PATIENTS UNDERGOING SURGERY IN FRANCE

    Nov 1, 2010, 00:00

  • PCV117 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

    Nov 1, 2010, 00:00

  • PGI8 HIDDEN COSTS OF ROTAVIRUS DISEASE-A RETROSPECTIVE MATCHED ANALYSIS OF HOSPITAL EPISODE STATISTICS (HES) DATA

    Nov 1, 2010, 00:00

  • PGI14 COST-EFFECTIVENESS ANALYSIS ON THE USE OF TEGASEROD COMPARED TO STANDARD THERAPY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITHIN AN INSTITUTIONAL SETTING IN MEXICO

    Nov 1, 2010, 00:00

  • PHP10 DOES THE MARKET SHARE OF GENERIC MEDICINES INFLUENCE THE PRICE LEVEL? A EUROPEAN ANALYSIS

    Nov 1, 2010, 00:00

  • PSY41 COST-EFFECTIVENESS OF BIOLOGICS IN PSORIASIS IN TWO LA COUNTRIES-COMPARISON WITH THE EUROPEAN EXPERIENCE

    Nov 1, 2010, 00:00

  • PSS24 QUALITY OF LIFE IN OCULAR HYPERTENSION AND PRIMARY OPEN ANGLE GLAUCOMA

    Nov 1, 2010, 00:00

  • PHP7 AN EXPLORATORY STUDY EVALUATING THE PREPAREDNESS OF PRACTICING COMMUNITY PHARMACISTS IN MALAYSIA FOR MANAGEMENT ROLES

    Nov 1, 2010, 00:00

  • PDB43 LONG-TERM COST-EFFECTIVENESS OF LIRAGLUTIDE VS. SULPHONYLUREA IN POLAND

    Nov 1, 2010, 00:00

  • PGI7 THE EFFECT OF ANTIVIRAL THERAPY ON QUALITY OF LIFE IN CHRONIC HEPATITIS PATIENTS-A SYSTEMATIC REVIEW

    Nov 1, 2010, 00:00

  • PCV69 COST-EFFECTIVENESS OF EPLERENONE COMPARED WITH SPIRONOLACTONE IN PATIENTS WITH HEART FAILURE AFTER ACUTE MYOCARDIAL INFARCTION

    Nov 1, 2010, 00:00

  • PMS33 COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE MANAGEMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE PREVIOUS DMARD THERAPY IN MEXICO

    Nov 1, 2010, 00:00

  • PIN18 COST-EFFECTIVENESS ANALYSIS OF UNIVERSAL NEWBORN VACCINATION AGAINST HEPATITIS B VIRUS IN VIETNAM

    Nov 1, 2010, 00:00

  • PIH51 AN ESTIMATE OF COSTS AND BENEFITS OF ALTERNATIVE METHODS OF DELIVERY- AN EMPIRICAL ANALYSIS IN AN ITALIAN HOSPITAL

    Nov 1, 2010, 00:00

  • PCV42 HOSPITALIZATION COSTS IN SOUTH KOREA FOR PATIENTS WITHOUT IDENTIFIED RISK FACTORS FOR BLEEDING WHO HAVE ACUTE CORONARY SYNDROMES WITH PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI ...

    Nov 1, 2010, 00:00

  • PMS21 THE ACUTE CARE COSTS OF OSTEOPOROSIS-RELATED FRACTURES IN CANADA

    Nov 1, 2010, 00:00

  • PIN51 UPDATING THE COST-EFFECTIVENESS OF ROTAVIRUS VACCINATION IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PCN36 DRUG UTILIZATION AND PRICE TRENDS OF ORAL-CHEMOTHERAPY MEDICATIONS IN MEDICAID 1991-2008

    Nov 1, 2010, 00:00

  • PHP30 VANCOMYCIN UTILIZATION EVALUATION IN A TEACHING HOSPITAL BETWEEN FEBRUARY 2007 AND MAY 2008 IN IRAN

    Nov 1, 2010, 00:00

  • PIN61 INFLUENZA RISK AND VACCINATION RATES IN EUROPE- A NATIONWIDE SURVEY OF ADULTS

    Nov 1, 2010, 00:00

  • PMC47 FURTHER INSIGHT INTO DESIGNING WEB-BASED PATIENT REPORTED OUTCOMES FOR USE ON PERSONAL COMPUTERS IN GLOBAL STUDIES

    Nov 1, 2010, 00:00

  • PCN10 ESTIMATION OF THE HEALTH AND COST BURDEN OF HPV-RELATED DISEASES IN THAILAND

    Nov 1, 2010, 00:00

  • PCV66 ECONOMIC PERFORMANCE OF DABIGATRAN ETEXILATE FOR PRIMARY VTE PREVENTION FOLLOWING TOTAL HIP AND KNEE REPLACEMENT SURGERY IN ITALY

    Nov 1, 2010, 00:00

  • PUK2 COMPARING THE RISK OF DEATH BETWEEN PERITONEAL DIALYSIS AND HEMODIALYSIS IN TAIWANS ESRD POPULATION

    Nov 1, 2010, 00:00

  • PCV82 COMMUNICATING COST-EFFECTIVENSS RATIOS TO DECISION MAKERS-THE CASE OF SWEDISH NATIONAL GUIDELINES FOR HEART DISEASES

    Nov 1, 2010, 00:00

  • PMS25 DIRECT MEDICAL COSTS OF OSTEOARTHRITIS IN SPAIN

    Nov 1, 2010, 00:00

  • PCN42 COSTS OF MANAGING ADVERSE EVENTS OF FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO- BEVACIZUMAB IN COMBINATION WITH INTERFERON-ALPHA-2A COMPARED WITH SUNITINIB

    Nov 1, 2010, 00:00

  • PCV142 AN APPLICATION OF IMPUTATION TECHNIQUES TO IMPROVE DATA AVAILABILITY FROM ELECTRONIC MEDICAL RECORDS

    Nov 1, 2010, 00:00

  • PRS30 DISCREPANCY BETWEEN ANALYTIC APPROACHES IN THE CLINICAL AND ECONOMIC EVALUATION OF THE SAME TRIAL- EXPERIENCE IN COPD

    Nov 1, 2010, 00:00

  • PMS2 DISABILITY OUTCOMES AND DOSE ESCALATION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR BLOCKERS- A COMPARATIVE EFFECTIVENESS ANALYSIS

    Nov 1, 2010, 00:00

  • PCV18 ECONOMIC EVALUATION OF USING HIGH-DOSE ATORVASTATIN FOR THE PREVENTION OF RECURRENT STROKE- EVIDENCE FROM THAILAND

    Nov 1, 2010, 00:00

  • PCN81 COST-EFFECTIVENESS ANALYSIS OF THREE STRATEGIES OF ERLOTINIB TREATMENT IN NON0-SMALL-CELL LUNG CANCER-A PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC)

    Nov 1, 2010, 00:00

  • PCN10 EXPLORATIVE ANALYSIS ABOUT THE POTENTIAL OF A LARGE GPS LONGITUDINAL DATABASE ON SEARCHING CAUSAL ASSOCIATIONS AMONG PATHOLOGIES

    Nov 1, 2010, 00:00

  • PSY54 THE DETERMINANTS OF HRQOL FOR PERSONS TAKING PRESCRIPTION PAIN MEDICATIONS- EVIDENCE FOR THE EUROPEAN UNION

    Nov 1, 2010, 00:00

  • DU3 ASSESSMENT OF THE KNOWLEDGE AND PERCEPTIONS OF THE MALAYSIAN COMMUNITY PHARMACISTS REGARDING PHARMACOVIGILANCE- FINDINGS FROM AN INTERVENTIONAL STUDY

    Nov 1, 2010, 00:00

  • PSS36 ECONOMIC ANALYSIS OF CATARACT SURGERY IN EUROPE-AN ANALYSIS OF HOSPITAL DATABASES AVAILABLE IN 11 COUNTRIES

    Nov 1, 2010, 00:00

  • PDB71 QUALITY-ADJUSTED LIFE-YEAR (QALY) WEIGHTS ASSOCIATED WITH DIFFERENT SEVERITY LEVELS OF DIABETIC RETINOPATHY

    Nov 1, 2010, 00:00

  • PCV23 DISCONTINUATION OF LOW-DOSE ACETYLSALICYLIC ACID TREATMENT FOR SECONDARY PREVENTION OF CARDIOVASCULAR OUTCOMES- INCIDENCE AND PREDICTORS

    Nov 1, 2010, 00:00

  • PDB21 IMPACT ASSESSMENT OF CBIA-DM STRATEGY ON DIABETIC PATIENTS QUALITY OF LIFE

    Nov 1, 2010, 00:00

  • PHP9 BUDGET IMPACT ANALYSIS OF ORPHAN DRUGS IN BELGIUM- ESTIMATES FROM 2008 TO 2013

    Nov 1, 2010, 00:00

  • PND3 EFFICACY AND TOLERABILITY OF INTERFERON-BETA IN ALL TYPE OF MULTIPLE SCLEROSIS

    Nov 1, 2010, 00:00

  • PCV8 LOST YEARS OF LIFE DUE TO DEATH FROM PULMONARY EMBOLISM IN HOSPITALIZED PATIENTS VERIFIED BY AUTOPSY FROM 1983 TILL 2005

    Nov 1, 2010, 00:00

  • PND7 ECONOMIC IMPACT OF PERSISTENCE TO DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF MULTIPLE SCLEROSIS

    Nov 1, 2010, 00:00

  • PIN1 SURGICAL SITE INFECTION IN CHINA- A SYSTEMATIC REVIEW OF THE INCIDENCE AND ECONOMIC BURDEN

    Nov 1, 2010, 00:00

  • PDB78 WILLINGNESS-TO-PAY FOR DIABETES DRUG THERAPY BASED ON META-ANALYSIS RESULTS

    Nov 1, 2010, 00:00

  • PND39 RESPONSIVENESS OF THE MULTIPLE SCLEROSIS INTERNATIONAL QUALITY OF LIFE QUESTIONNAIRE TO EXPANDED DISABILITY STATUS SCALE SCORE CHANGES IN PATIENTS WITH MULTIPLE SCLEROSIS- MONTH 12 RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDY

    Nov 1, 2010, 00:00

  • PSS28 DEVELOPMENT OF AN INSTRUMENT MIRRORING PATIENT AND PHYSICIAN PERCEPTION OF PSORIASIS SEVERITY AND TREATMENT EFFECT

    Nov 1, 2010, 00:00

  • PCN112 PATIENT CHARACTERISTICS, MEDICATION USE, RESOURCE USE AND MEDICAL COSTS AMONG PATIENTS WITH METASTATIC PANCREATIC CANCER (MPC)

    Nov 1, 2010, 00:00

  • PRS28 ECONOMIC EVALUATION OF FLUTICASONE PROPIONATE/ SALMETEROL COMBINATION THERAPY AND MONTELUKAST IN ADULT PATIENTS WHO ARE SYMPTOMATIC ON SHORT-ACTING BETA 2-AGONIST ALONE

    Nov 1, 2010, 00:00

  • PMC3 A NOVEL APPROACH TO MATCHING ADJUSTED INDIRECT COMPARISON ANALYSIS USING COMMON SAS 9.2 PROCEDURES

    Nov 1, 2010, 00:00

  • DU4 COST-EFFECTIVENESS ANALYSIS OF TRAVOPROST FOLLOWED BY FIXED COMBINATION TRAVOPROST/TIMOLOL TREATMENT SEQUENCE (T-TTFC) COMPARED TO LATANOPROST FOLLOWED BY LATANOPROST/TIMOLOL FIXED COMBINATION (L-LTFC) FOR PATIENTS WITH OPEN ANGLE GLAUC ...

    Nov 1, 2010, 00:00

  • PUK19 ECONOMIC EVALUATION OF ALISKIREN IN TYPE 2 DIABETES AND HYPERTENSION PATIENTS WITH NEPHROPATHY IN MEXICO

    Nov 1, 2010, 00:00

  • PMS48 PSYCHOMETRIC PROPERTIES OF THE GREEK MODIFIED HEALTH ASSESSMENT QUESTIONNAIRE FOR ASSESSING PHYSICAL DISABILITY IN RHEUMATOID ARTHRITIS

    Nov 1, 2010, 00:00

  • PSS9 COSTS OF GLAUCOMA IN SWEDEN-A PILOT STUDY

    Nov 1, 2010, 00:00

  • PIH13 COMPLIANCE WITH HORMONE THERAPY AMONG MENOPAUSAL WOMEN AFTER THE WHI PUBLICATION IN TAIWAN

    Nov 1, 2010, 00:00

  • PSS6 ASTIGMATISM AND COST OF POST-CATARACT SURGERY SPECTACLE WEAR IN KOREA

    Nov 1, 2010, 00:00

  • PHP25 DOES HUMAN MEDICINES DEVELOPMENT IN THE EUROPEAN UNION ADDRESS GLOBAL AND REGIONAL HEALTH CONCERNS?

    Nov 1, 2010, 00:00

  • PHP116 ANALYSIS OF ANTICOAGULATION BRIDGING THERAPY IN ORTHOPEDIC PATIENTS- REAL WORLD ANALYSIS

    Nov 1, 2010, 00:00

  • PCV31 BLOOD PRESSURE CONTROL AND ANTIHYPERTENSIVE STRATEGY DIFFERENCES ACCORDING TO PATIENTS AGE

    Nov 1, 2010, 00:00

  • PHP135 THE EXAMINATION OF THE CHRONIC STRESS

    Nov 1, 2010, 00:00

  • PDB45 COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN SPAIN

    Nov 1, 2010, 00:00

  • PHP10 USING ASSET INDEX FOR MEASURING HOUSEHOLD LIVING STANDARDS AND MONITORING HEALTH EQUITY IN THAILAND

    Nov 1, 2010, 00:00

  • PCV123 EPIDEMIOLOGICAL STUDY OF EUROPEAN CARDIOVASCULAR RISK PATIENTS- DISEASE PREVENTION AND MANAGEMENT IN USUAL DAILY PRACTICE-TURKISH RESULTS OF EURIKA STUDY

    Nov 1, 2010, 00:00

  • PCV30 PREVALENCE AND CONTROL OF TRADITIONAL CARDIOVASCULAR RISK FACTORS AND ANTICIPATED AVOIDABLE CORONARY MORTALITY IN PRIMARY PREVENTION IN EUROPE-THE EURIKA STUDY

    Nov 1, 2010, 00:00

  • PUK21 LONG-TERM COST-EFFECTIVENESS OF SIROLIMUS BASED REGIMEN COMPARED WITH CALCINEURIN INHIBITOR BASED REGIMENS IN LOWER IMMUNOLOGICAL RISK RENAL TRANSPLANT RECIPIENTS IN KOREA

    Nov 1, 2010, 00:00

  • PMH10 COST SAVING POTENTIAL OF GENERIC SUBSTITUTION-THE CASE OF ANTIDEPRESSANTS

    Nov 1, 2010, 00:00

  • PMH48 IMPACT OF ONCE-DAILY DOSING ON DRUG DISCONTINUATION OF PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2010, 00:00

  • PHP1 ORPHAN DRUGS- DOES SOCIETY VALUE RARITY?

    Nov 1, 2010, 00:00

  • PMH17 COST OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER IN GERMANY

    Nov 1, 2010, 00:00

  • PHP15 DRUG COMPARATOR DIFFERENCES IN THE THERAPEUTIC BULLETINS IN SPAIN-THE JCNDE EXPERIENCE

    Nov 1, 2010, 00:00

  • PMS76 A LONGITUDINAL COMPARISON OF MAPPING EQUATIONS DERIVED FROM BASELINE AND POST-INTERVENTION DATA

    Nov 1, 2010, 00:00

  • PUK3 ASSESSMENT OF COMORBIDITIES IN PATIENTS WITH OVERACTIVE BLADDER (OAB) DISORDER- AN ELECTRONIC MEDICAL RECORD (EMR) DATA ANALYSIS

    Nov 1, 2010, 00:00

  • PCV138 MEASUREMENT PROPERTIES OF PEAK VO2 IN CHILDREN WITH PULMONARY ARTERIAL HYPERTENSION

    Nov 1, 2010, 00:00

  • PCN160 THE ROLE OF PATIENT SELECTION CRITERIA IN IDENTIFYING OVARIAN CANCER PATIENTS

    Nov 1, 2010, 00:00

  • RS4 THE INFLUENCE OF UK RISK-SHARING MODELS (PATIENT ACCESS SCHEMES) ON PAYERS IN GERMANY AND THE NETHERLANDS. A QUALITATIVE RESEARCH APPROACH

    Nov 1, 2010, 00:00

  • PND26 MEDICO-ECONOMIC EVALUATION OF LACOSAMIDE ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH REFRACTORY EPILEPSY IN SCOTLAND AND SPAIN

    Nov 1, 2010, 00:00

  • PIN62 AN ECONOMIC EVALUATION OF HIBMENCY VACCINATION FOR THE PREVENTION OF HEMOPHILUS INFLUENZAE TYPE B AND NEISSERIA MENINGITIDIS TYPES C AND Y

    Nov 1, 2010, 00:00

  • PIH40 METHODOLOGICAL CONSIDERATIONS WHEN ASSESSING WORK PRODUCTIVITY (WP) AND ACTIVITIES OF DAILY LIVING (ADL) OUTCOMES IN MULTINATIONAL CLINICAL TRIALS IN WOMEN WITH HEAVY AND/OR PROLONGED MENSTRUAL BLEEDING (HPMB) TREATED WITH ESTRADIOL V ...

    Nov 1, 2010, 00:00

  • PHP37 THE IMPACT OF UNIVERSAL COVERAGE ON EQUITY IN HEALTH CARE FINANCE AND FINANCIAL RISK PROTECTION IN THAILAND

    Nov 1, 2010, 00:00

  • PDB69 UTILITY VALUES FOR DIABETES COMPLICATIONS

    Nov 1, 2010, 00:00

  • PCV21 MODELING THE COST-EFFECTIVENESS OF CORONARY COMPUTED TOMOGRAPHY FOR PATIENTS WITH CHEST PAIN USING BOTH DIAGNOSTIC AND PROGNOSTIC INFORMATION

    Nov 1, 2010, 00:00

  • PDB20 A PHARMACOECONOMIC MODEL FOR ADJUVANT TREATMENT IN A SMOKING CESSATION INTERVENTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Nov 1, 2010, 00:00

  • PHP5 PATIENT DISCHARGE FROM INTENSIVE CARE UNITS WITHIN AND BETWEEN HOSPITALS IN HUNGARY

    Nov 1, 2010, 00:00

  • PIN5 HOW LONGITUDINAL PATIENT RECORDS CAN HELP PUBLIC HEALTH AUTHORITIES IN THE MANAGEMENT OF RAPIDLY GROWING EPIDEMICS? THE EXPERIENCE OF FLU A/H1N1 IN FRANCE

    Nov 1, 2010, 00:00

  • PDB7 PREDICTORS FOR THE INITIATION OF A BASAL SUPPORTED ORAL THERAPY (BOT) IN TYPE 2 DIABETIC PATIENTS UNDER REAL-LIFE CONDITIONS IN GERMANY

    Nov 1, 2010, 00:00

  • PDB61 ECONOMIC EVALUATION OF LIRAGLUTIDE VS. ROSIGLITAZONE OR EXENATIDE FOR TYPE 2 DIABETES MELLITUS IN BULGARIA

    Nov 1, 2010, 00:00

  • ISPOR 13TH ANNUAL EUROPEAN CONGRESS DISCLOSURE INFORMATION

    Nov 1, 2010, 00:00
  • «
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136 (current)
  • 137
  • 138
  • 139
  • 140
  • »